Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Bortezomib vs no bortezomib Treatment‐related death ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma Bortezomib for the treatment of multiple myeloma (2016) · Cochrane | OR 0.73 [0.36, 1.48] | 3 studies · 1652 participants | Very low |
Thrombopoietin mimetics vs placebo or standard care Number of participants with at least 1 bleeding episode · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | OR 0.4 [0.1, 1.62] | 1 study · 120 participants | Very low |
Intervention NR Number of participants with severe or life‐threatening bleeding · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | OR 4 [0.56, 28.4] | 1 study · 18 participants | Very low |
Intervention NR Number of days on which bleeding occurred ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Time from randomisation to first bleeding episode ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of platelet transfusions ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Thromboembolic events ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Thrombopoietin mimetics vs placebo or standard care Number of participants with severe or life‐threatening bleeding · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | OR 1.46 [0.06, 33.14] | 3 studies · 209 participants | Very low |
Thrombopoietin mimetics vs placebo or standard care Number of days on which bleeding occurred ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Thrombopoietin mimetics vs placebo or standard care Time from randomisation to first bleeding episode ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Thrombopoietin mimetics vs placebo or standard care All‐cause mortality · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | 4 participants | Ungraded |
Thrombopoietin mimetics vs placebo or standard care Number of platelet transfusions · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | 1 study · 120 participants | Very low |
Thrombopoietin mimetics vs placebo or standard care Thromboembolic events · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | 2 studies · 209 participants | Very low |
Thrombopoietin mimetics vs placebo or standard care Quality of life ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of participants with at least 1 bleeding episode · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… (2016) · Cochrane | OR 16 [1.32, 194.62] | 1 study · 18 participants | Very low |
Intervention NR Overall survival · adult patients with haematological malignancies Meditation for adults with haematological malignancies (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · adult patients with haematological malignancies Meditation for adults with haematological malignancies (2016) · Cochrane | no estimate extracted | 1 study · 42 participants | Very low |
Intervention NR Fatigue · adult patients with haematological malignancies Meditation for adults with haematological malignancies (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Anxiety · adult patients with haematological malignancies Meditation for adults with haematological malignancies (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Depression · adult patients with haematological malignancies Meditation for adults with haematological malignancies (2016) · Cochrane | no estimate extracted | 1 study · 42 participants | Very low |
Intervention NR Quality of sleep · adult patients with haematological malignancies Meditation for adults with haematological malignancies (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · adult patients with haematological malignancies Meditation for adults with haematological malignancies (2016) · Cochrane | no estimate extracted | NR | No studies |
Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion Major procedure‐related bleeding · people with abnormal coagulation requiring a central venous catheter Plasma transfusions prior to insertion of central lines for people with abnormal coagulation (2016) · Cochrane | no estimate extracted | 1 study · 58 participants | Very low |
Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion All‐cause mortality · people with abnormal coagulation requiring a central venous catheter Plasma transfusions prior to insertion of central lines for people with abnormal coagulation (2016) · Cochrane | no estimate extracted | NR | No studies |
Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion Respiratory deterioration attributable to transfusion‐associated circulatory overload (TACO), transfusion‐related acute lung injury (TRALI) or transfusion‐associated dyspnoea (TAD) · people with abnormal coagulation requiring a central venous catheter Plasma transfusions prior to insertion of central lines for people with abnormal coagulation (2016) · Cochrane | no estimate extracted | NR | No studies |
Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion Minor procedure‐related bleeding · people with abnormal coagulation requiring a central venous catheter Plasma transfusions prior to insertion of central lines for people with abnormal coagulation (2016) · Cochrane | RR 0.67 [0.12, 3.7] | 1 study · 58 participants | Very low |
Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion Proportion of participants receiving plasma transfusions · people with abnormal coagulation requiring a central venous catheter Plasma transfusions prior to insertion of central lines for people with abnormal coagulation (2016) · Cochrane | no estimate extracted | NR | No studies |
Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion Line‐related complications · people with abnormal coagulation requiring a central venous catheter Plasma transfusions prior to insertion of central lines for people with abnormal coagulation (2016) · Cochrane | no estimate extracted | NR | No studies |
Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion Quality of life · people with abnormal coagulation requiring a central venous catheter Plasma transfusions prior to insertion of central lines for people with abnormal coagulation (2016) · Cochrane | no estimate extracted | NR | No studies |
Thrombopoietin mimetic vs placebo Number of participants with at least one bleeding episode · People with chronic bone marrow failure Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with… (2016) · Cochrane | RR 0.86 [0.56, 1.31] | 4 studies · 206 participants | Low |
Thrombopoietin mimetic vs placebo Number of participants with at least one severe or life‐threatening bleeding episode · People with chronic bone marrow failure Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with… (2016) · Cochrane | RR 0.31 [0.04, 2.26] | 1 study · 40 participants | Low |
Thrombopoietin mimetic vs placebo All‐cause mortality · People with chronic bone marrow failure Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with… (2016) · Cochrane | RR 0.74 [0.52, 1.05] | 5 studies · 456 participants | Very low |
Thrombopoietin mimetic vs placebo Proportion of participants receiving a platelet transfusion · People with chronic bone marrow failure Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with… (2016) · Cochrane | RR 0.76 [0.61, 0.95] | 4 studies · 206 participants | Moderate |
Thrombopoietin mimetic vs placebo Transfusion reactions · People with chronic bone marrow failure Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with… (2016) · Cochrane | 0.06 [0, 3.44] | 1 study · 98 participants | Very low |
Thrombopoietin mimetic vs placebo Thromboembolism · People with chronic bone marrow failure Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with… (2016) · Cochrane | RR 1.41 [0.39, 5.01] | 5 studies · 456 participants | Very low |
Thrombopoietin mimetic vs placebo Drug reactions · People with chronic bone marrow failure Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with… (2016) · Cochrane | RR 1.12 [0.83, 1.51] | 5 studies · 455 participants | Low |
Thrombopoietin mimetic vs placebo Number of red cell transfusions per participant · People with chronic bone marrow failure Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with… (2016) · Cochrane | no estimate extracted | 1 study · 98 participants | Ungraded |
Intervention NR All cause mortality · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Incidence of severe infections (Grade III or IV) · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | RR 1.55 [0.86, 2.8] | 1 study · 115 participants | Low |
Intervention NR Adverse events Toxic deaths · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | RR 1.32 [0.3, 5.69] | 1 study · 115 participants | Low |
Intervention NR Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | 1 study · 40 participants | Very low |
Intervention NR Quality of life · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | RR 1.22 [0.53, 2.84] | 1 study · 40 participants | Very low |
Intervention NR Incidence of severe infections · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All cause mortality · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | 1 study · 115 participants | Low |
Intervention NR Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer… (2015) · Cochrane | no estimate extracted | NR | No studies |